Epidemiological observations on theileriosis following field immunisation using infection and treatment.
Thirty-seven high grade cattle were immunised against Corridor disease (Theileria parva lawrencei infection) on a farm with a history of heavy and often lethal theilerial challenge. Nineteen cattle were immunised by treating with two doses of long-acting oxytetracyclines given at 20 mg/kg on days 0 and 4 after sporozoite stabilate inoculation, while the other 18 were treated with naphthoquinone buparvaquone, given as a single dose of 2.5 mg/kg simultaneously with stabilate inoculation. All the cattle underwent subclinical theilerial reactions with all but two developing high antibody titres on the IFAT test against T. parva schizont antigen by day 35 after the immunisation. Both buparvaquone and long-acting oxytetracycline appeared equally effective in the immunisation. To date, 26 months later, only two cases of theileriosis parasitologically characteristic of T. p. parva have been reported in the immunised cattle. Following the two cases, investigations showed that when uninfected Rhipicephalus appendiculatus nymphal ticks were deliberately fed on healthy resident cattle on the farm, the resultant adult ticks transmitted acute and lethal theilerial infections to five out of five susceptible cattle. The resultant infections were parasitologically characteristic of T. p. parva infections. Furthermore, the monoclonal antibody profiles of schizont infected cell lines from these infections appeared to be characteristic of T. p. parva. It was thus concluded that resident cattle on the farm could be a potential source of T.p. parva infection which had broken through the immunity of T.p. lawrencei immunised cattle and could constitute a reservoir of theilerial infection for ticks and hence to susceptible stock on the farm.
Mutugi
J J
JJ
National Veterinary Research Centre, Muguga, Kenya.
Young
A S
AS
Kariuki
D P
DP
Tameno
J M
JM
Morzaria
S P
SP
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D016782:Apicomplexa / Q000276:immunology; D001096:Arachnid Vectors / Q000469:parasitology; D002353:Carrier State / Q000662:veterinary; D002417:Cattle; D004197:Disease Reservoirs; D005260:Female; D005455:Fluorescent Antibody Technique; D007114:Immunization / Q000662:veterinary*; D008297:Male; D009285:Naphthoquinones / Q000627:therapeutic use*; D009758:Nymph / Q000469:parasitology; D010118:Oxytetracycline / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000517:prevention & control / Q000662:veterinary; D013801:Theileriasis / Q000188:drug therapy / Q000517:prevention & control* / Q000635:transmission; D013987:Ticks / Q000469:parasitology
D000913:Antibodies, Protozoan; D000981:Antiprotozoal Agents; D009285:Naphthoquinones; C046326:buparvaquone; D010118:Oxytetracycline